AIM: To investigate the relationship between osteopontin plasma concentrations and the severity of portal hypertension and to assess osteopontin prognostic value. METHODS: A cohort of 154 patients with confirmed liver cirrhosis (112 ethylic, 108 men, age 34-72 years) were enrolled in the study. Hepatic venous pressure gradient (HVPG) measurement and laboratory and ultrasound examinations were carried out for all patients. HVPG was measured using a standard catheterization method with the balloon wedge technique. Osteopontin was measured using the enzyme-linked immunosorbent assay (ELISA) method in plasma. Patients were followed up with a specific focus on mortality. The control group consisted of 137 healthy age- and sex- matched individuals. RESULTS: The mean value of HVPG was 16.18 ± 5.6 mmHg. Compared to controls, the plasma levels of osteopontin in cirrhotic patients were significantly higher (P < 0.001). The plasma levels of osteopontin were positively related to HVPG (P = 0.0022, r = 0.25) and differed among the individual Child-Pugh groups of patients. The cut-off value of 80 ng/mL osteopontin distinguished patients with significant portal hypertension (HVPG above 10 mmHg) at 75% sensitivity and 63% specificity. The mean follow-up of patients was 3.7 ± 2.6 years. The probability of cumulative survival was 39% for patients with HVPG > 10 mmHg and 65% for those with HVPG ≤ 10 mmHg (P = 0.0086, odds ratio (OR), 2.92, 95% confidence interval (CI): 1.09-7.76). Osteopontin showed a similar prognostic value to HVPG. Patients with osteopontin values above 80 ng/mL had significantly lower cumulative survival compared to those with osteopontin ≤ 80 ng/mL (37% vs 56%, P = 0.00035; OR = 2.23, 95%CI: 1.06-4.68). CONCLUSION: Osteopontin is a non-invasive parameter of portal hypertension that distinguishes patients with clinically significant portal hypertension. It is a strong prognostic factor for survival.

Radan Bruha Jaromir Petrtyl Karel Dvorak Tomislav Svestka 4 Department of Internal Medicine 1 Faculty of Medicine and General University Hospital Charles University Prague 12808 Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc17013984

003      

CZ-PrNML

005      

20170425122809.0

007      

ta

008      

170413s2016 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.3748/wjg.v22.i12.3441 $2 doi

035    __

$a (PubMed)27022226

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Bruha, Radan $u Radan Bruha, Jaromir Petrtyl, Karel Dvorak, Tomislav Svestka, 4 Department of Internal Medicine, 1 Faculty of Medicine and General University Hospital, Charles University in Prague, 12808 Prague, Czech Republic.

245    10

$a Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis / $c R. Bruha, M. Jachymova, J. Petrtyl, K. Dvorak, M. Lenicek, P. Urbanek, T. Svestka, L. Vitek,

520    9_

$a AIM: To investigate the relationship between osteopontin plasma concentrations and the severity of portal hypertension and to assess osteopontin prognostic value. METHODS: A cohort of 154 patients with confirmed liver cirrhosis (112 ethylic, 108 men, age 34-72 years) were enrolled in the study. Hepatic venous pressure gradient (HVPG) measurement and laboratory and ultrasound examinations were carried out for all patients. HVPG was measured using a standard catheterization method with the balloon wedge technique. Osteopontin was measured using the enzyme-linked immunosorbent assay (ELISA) method in plasma. Patients were followed up with a specific focus on mortality. The control group consisted of 137 healthy age- and sex- matched individuals. RESULTS: The mean value of HVPG was 16.18 ± 5.6 mmHg. Compared to controls, the plasma levels of osteopontin in cirrhotic patients were significantly higher (P < 0.001). The plasma levels of osteopontin were positively related to HVPG (P = 0.0022, r = 0.25) and differed among the individual Child-Pugh groups of patients. The cut-off value of 80 ng/mL osteopontin distinguished patients with significant portal hypertension (HVPG above 10 mmHg) at 75% sensitivity and 63% specificity. The mean follow-up of patients was 3.7 ± 2.6 years. The probability of cumulative survival was 39% for patients with HVPG > 10 mmHg and 65% for those with HVPG ≤ 10 mmHg (P = 0.0086, odds ratio (OR), 2.92, 95% confidence interval (CI): 1.09-7.76). Osteopontin showed a similar prognostic value to HVPG. Patients with osteopontin values above 80 ng/mL had significantly lower cumulative survival compared to those with osteopontin ≤ 80 ng/mL (37% vs 56%, P = 0.00035; OR = 2.23, 95%CI: 1.06-4.68). CONCLUSION: Osteopontin is a non-invasive parameter of portal hypertension that distinguishes patients with clinically significant portal hypertension. It is a strong prognostic factor for survival.

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a biologické markery $x krev $7 D015415

650    _2

$a studie případů a kontrol $7 D016022

650    _2

$a progrese nemoci $7 D018450

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a portální hypertenze $x krev $x diagnóza $x mortalita $x patofyziologie $7 D006975

650    _2

$a Kaplanův-Meierův odhad $7 D053208

650    _2

$a lineární modely $7 D016014

650    _2

$a jaterní cirhóza $x krev $x diagnóza $x mortalita $x patofyziologie $7 D008103

650    _2

$a logistické modely $7 D016015

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a odds ratio $7 D016017

650    _2

$a osteopontin $x krev $7 D053495

650    12

$a portální tlak $7 D017082

650    _2

$a prediktivní hodnota testů $7 D011237

650    _2

$a prognóza $7 D011379

650    _2

$a prospektivní studie $7 D011446

650    _2

$a rizikové faktory $7 D012307

650    _2

$a stupeň závažnosti nemoci $7 D012720

650    _2

$a časové faktory $7 D013997

650    _2

$a upregulace $7 D015854

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Jachymova, Marie $u Radan Bruha, Jaromir Petrtyl, Karel Dvorak, Tomislav Svestka, 4 Department of Internal Medicine, 1 Faculty of Medicine and General University Hospital, Charles University in Prague, 12808 Prague, Czech Republic.

700    1_

$a Petrtyl, Jaromir $u Radan Bruha, Jaromir Petrtyl, Karel Dvorak, Tomislav Svestka, 4 Department of Internal Medicine, 1 Faculty of Medicine and General University Hospital, Charles University in Prague, 12808 Prague, Czech Republic.

700    1_

$a Dvorak, Karel $u Radan Bruha, Jaromir Petrtyl, Karel Dvorak, Tomislav Svestka, 4 Department of Internal Medicine, 1 Faculty of Medicine and General University Hospital, Charles University in Prague, 12808 Prague, Czech Republic.

700    1_

$a Lenicek, Martin $u Radan Bruha, Jaromir Petrtyl, Karel Dvorak, Tomislav Svestka, 4 Department of Internal Medicine, 1 Faculty of Medicine and General University Hospital, Charles University in Prague, 12808 Prague, Czech Republic.

700    1_

$a Urbanek, Petr $u Radan Bruha, Jaromir Petrtyl, Karel Dvorak, Tomislav Svestka, 4 Department of Internal Medicine, 1 Faculty of Medicine and General University Hospital, Charles University in Prague, 12808 Prague, Czech Republic.

700    1_

$a Svestka, Tomislav $u Radan Bruha, Jaromir Petrtyl, Karel Dvorak, Tomislav Svestka, 4 Department of Internal Medicine, 1 Faculty of Medicine and General University Hospital, Charles University in Prague, 12808 Prague, Czech Republic.

700    1_

$a Vitek, Libor $u Radan Bruha, Jaromir Petrtyl, Karel Dvorak, Tomislav Svestka, 4 Department of Internal Medicine, 1 Faculty of Medicine and General University Hospital, Charles University in Prague, 12808 Prague, Czech Republic.

773    0_

$w MED00006918 $t World journal of gastroenterology $x 2219-2840 $g Roč. 22, č. 12 (2016), s. 3441-50

856    41

$u https://pubmed.ncbi.nlm.nih.gov/27022226 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20170413 $b ABA008

991    __

$a 20170425123126 $b ABA008

999    __

$a ok $b bmc $g 1200449 $s 974762

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2016 $b 22 $c 12 $d 3441-50 $i 2219-2840 $m World journal of gastroenterology $n World J. Gastroenterol. $x MED00006918

LZP    __

$a Pubmed-20170413